Your browser doesn't support javascript.
loading
Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants.
Moriyama, Saya; Adachi, Yu; Sato, Takashi; Tonouchi, Keisuke; Sun, Lin; Fukushi, Shuetsu; Yamada, Souichi; Kinoshita, Hitomi; Nojima, Kiyoko; Kanno, Takayuki; Tobiume, Minoru; Ishijima, Keita; Kuroda, Yudai; Park, Eun-Sil; Onodera, Taishi; Matsumura, Takayuki; Takano, Tomohiro; Terahara, Kazutaka; Isogawa, Masanori; Nishiyama, Ayae; Kawana-Tachikawa, Ai; Shinkai, Masaharu; Tachikawa, Natsuo; Nakamura, Shigeki; Okai, Takahiro; Okuma, Kazu; Matano, Tetsuro; Fujimoto, Tsuguto; Maeda, Ken; Ohnishi, Makoto; Wakita, Takaji; Suzuki, Tadaki; Takahashi, Yoshimasa.
Afiliação
  • Moriyama S; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Adachi Y; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Sato T; Tokyo Shinagawa Hospital, Tokyo, 140-8522, Japan.
  • Tonouchi K; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan; Department of Life Science and Medical Bioscience, Waseda University, Tokyo, 162-8480, Japan.
  • Sun L; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Fukushi S; Department of Virology I, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Yamada S; Department of Virology I, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Kinoshita H; Department of Virology I, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Nojima K; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, 208-0011, Japan.
  • Kanno T; Department of Pathology, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Tobiume M; Department of Pathology, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Ishijima K; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Kuroda Y; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Park ES; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Onodera T; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Matsumura T; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Takano T; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Terahara K; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Isogawa M; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Nishiyama A; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Kawana-Tachikawa A; AIDS Research Center, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Shinkai M; Tokyo Shinagawa Hospital, Tokyo, 140-8522, Japan.
  • Tachikawa N; Yokohama Municipal Citizen's Hospital, Kanagawa, 221-0855, Japan.
  • Nakamura S; Tokyo Medical University, Tokyo, 160-8402, Japan.
  • Okai T; Kawakita General Hospital, Tokyo, 166-0001, Japan.
  • Okuma K; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, 208-0011, Japan.
  • Matano T; AIDS Research Center, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Fujimoto T; Center for Emergency Preparedness and Response, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Maeda K; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Ohnishi M; National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Wakita T; National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Suzuki T; Department of Pathology, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Takahashi Y; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan. Electronic address: ytakahas@niid.go.jp.
Immunity ; 54(8): 1841-1852.e4, 2021 08 10.
Article em En | MEDLINE | ID: mdl-34246326
ABSTRACT
Antibody titers against SARS-CoV-2 slowly wane over time. Here, we examined how time affects antibody potency. To assess the impact of antibody maturation on durable neutralizing activity against original SARS-CoV-2 and emerging variants of concern (VOCs), we analyzed receptor binding domain (RBD)-specific IgG antibodies in convalescent plasma taken 1-10 months after SARS-CoV-2 infection. Longitudinal evaluation of total RBD IgG and neutralizing antibody revealed declining total antibody titers but improved neutralization potency per antibody to original SARS-CoV-2, indicative of antibody response maturation. Neutralization assays with authentic viruses revealed that early antibodies capable of neutralizing original SARS-CoV-2 had limited reactivity toward B.1.351 (501Y.V2) and P.1 (501Y.V3) variants. Antibodies from late convalescents exhibited increased neutralization potency to VOCs, suggesting persistence of cross-neutralizing antibodies in plasma. Thus, maturation of the antibody response to SARS-CoV-2 potentiates cross-neutralizing ability to circulating variants, suggesting that declining antibody titers may not be indicative of declining protection.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Neutralizantes / SARS-CoV-2 / COVID-19 / Anticorpos Antivirais Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Neutralizantes / SARS-CoV-2 / COVID-19 / Anticorpos Antivirais Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão